Areas of Research on Low-Dose Nutritional Lithium: What Studies Have Explored
Posted by Elisa Medhus, M.D. on July 31, 2026

Areas of Research on Low-Dose Nutritional Lithium: What Studies Have Explored

Lithium has been studied across many areas of biology and health, using different doses, formulations, populations, and experimental models. This article provides an educational overview of research topics involving low-dose and trace-level lithium. It does not mean that every finding applies to lithium orotate, to dietary supplementation, or to VitalithMD® specifically.

Please read this before continuing. VitalithMD® is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. Much of the research described below involves prescription-dose lithium carbonate, animal models, cell-based experiments, or population-level observational data. Research of those kinds should not be interpreted as proof that a low-dose nutritional supplement produces the same outcome. Where a study involved a named disease, that study investigated the disease — it did not establish that any supplement prevents or treats it.

Prescription lithium (lithium carbonate) is typically dosed in the hundreds to over a thousand milligrams per day and requires regular blood monitoring. Low-dose lithium orotate supplements provide a small fraction of that amount, which is the basis for their classification as a nutritional ingredient rather than a medication. This distinction matters when reading any of the research below.

Research Areas: Nervous System and Mood

The largest body of research on lithium centers on the nervous system. A 2025 study published in Nature examined lithium levels in relation to amyloid accumulation and cognitive decline in Alzheimer's disease [1]. Other preclinical work has investigated lithium's action on WNT/β-catenin signaling and oxidative stress pathways in Parkinson's disease models [2]. Researchers have also studied lithium in the context of traumatic brain injury recovery [3] and motor recovery following ischemic stroke [4]. Broader reviews have examined proposed neuroprotective mechanisms involving oxidative stress and inflammation [5], and clinical studies have looked at cluster headache prophylaxis [6] and neurological symptoms associated with Lyme disease [7]. These are areas of investigation, not demonstrated outcomes of supplementation.

Some studies have measured changes in brain structure and chemistry. MRI research reported increases in gray matter volume after four weeks of lithium treatment in a clinical population [8]. Animal studies have found that chronic lithium administration raised BDNF (brain-derived neurotrophic factor) levels in the rat hippocampus [9]. At the molecular level, researchers have explored lithium's influence on gene expression tied to BDNF in animal models [10] and its role in histone acetylation, an epigenetic mechanism studied in relation to memory and cognition [12].

A separate cluster of studies has investigated lithium in relation to mood and behavior. This includes a randomized controlled trial in bulimia nervosa [13], studies on cravings related to alcohol and other substance use [14], and meta-analyses examining suicide risk in mood disorder populations receiving prescription lithium [15]. Ecological research has examined correlations between trace lithium levels in drinking water and regional crime statistics [16] — correlational population data, which cannot establish cause and effect. Clinical studies have also investigated irritability and aggression [17][18], behavioral dysregulation in autism [19], anxiety in bipolar depression [20], PTSD in a case series [21], OCD augmentation [22], stress resilience [23], sleep and racing thoughts [24], impulsivity in children with ADHD [25], and premenstrual syndrome [26]. The majority of these involved prescription dosing in clinical populations.

Research Areas: Aging and Longevity

Aging research on lithium has largely focused on inflammation and cellular stress. Studies have investigated whether lithium modulates inflammatory cytokines such as IL-6 and TNF-alpha [27][28], with researchers proposing anti-inflammatory activity as one hypothesized mechanism relevant to age-related decline [29]. Other research has examined lithium's relationship to telomere length, a marker sometimes used as a proxy for cellular aging [30].

At the population level, ecological studies have correlated trace lithium levels in regional drinking water with average lifespan [31][32]. These are observational correlations at a population level and do not establish that supplementation extends individual lifespan.

Research Areas: Cardiovascular and Metabolic

Population studies in Japan have examined associations between lithium levels in drinking water and all-cause mortality [33] and cardiovascular disease mortality [34]. These are ecological analyses. Mechanistically, researchers have proposed hypotheses involving endothelial function and nitric oxide availability [35], and separate preclinical work has examined vascular oxidative stress [36].

On the metabolic side, studies in animal models and in bipolar patient populations have examined lithium's relationship to insulin sensitivity and glucose regulation [37], and other research has looked at appetite and cravings [38].

Research Areas: Liver, Gut, and Cellular Processes

Preclinical liver research has explored lithium in models of fatty liver disease, hepatitis, cirrhosis, and NASH [39], and its effect on liver damage from certain toxins in animal models [40]. Separately, researchers have begun examining lithium's influence on gut microbiota composition and downstream immune regulation [41]. At the cellular level, studies have investigated lithium's role in autophagy, the process by which cells clear damaged proteins [42] — a mechanism of interest in both aging and neurodegenerative research. This work is preclinical.

Research Areas: Bone and Cancer Epidemiology

Preclinical research has examined lithium's effects on bone formation through Wnt signaling, reporting increased osteoblast activity and bone mass in animal models [43], with related work on bone loss in ovariectomized rat models of osteoporosis [44].

Separately, population-based cohort studies have examined associations between prescription lithium use in bipolar disorder populations and cancer incidence [45], as well as cancer-specific mortality [46]. These are observational associations drawn from psychiatric-dose populations. They are not findings about nutritional lithium orotate and should be read as a direction for further research rather than a settled result.

Additional Research Areas

Researchers have also studied lithium in relation to immune function and antiviral response [46], intraocular pressure in glaucoma [47], symptom reporting in an open-label fibromyalgia study [48], gene regulation through GSK-3β inhibition [49], and lung inflammation in a preclinical sepsis model [50].

Questions About Low-Dose Nutritional Lithium

What does the research on low-dose lithium orotate actually show?
Research spans the areas described above. Most of it is preclinical, population-based, or drawn from prescription-dose studies. It is best understood as an active area of scientific investigation rather than a list of established outcomes for a dietary supplement.

How is lithium orotate different from prescription lithium?
Prescription lithium (lithium carbonate) is dosed to treat bipolar disorder and requires regular blood monitoring. Lithium orotate supplements are formulated at a much lower, nutritional dose and are not intended to treat any psychiatric condition.

Is there scientific research on lithium orotate specifically?
The findings above draw on a mix of clinical trials, population studies, and preclinical research, most of which used lithium forms and doses other than nutritional lithium orotate. The full reference list is below so you can review the original sources and study designs yourself.

Who should talk to a doctor first?
Anyone who is pregnant or nursing, taking prescription medication (especially other mood-stabilizing or psychiatric medications), or managing a kidney, thyroid, or cardiovascular condition should check with a healthcare provider before using any dietary supplement.

Read the Primary Sources

The full reference list appears below. We encourage readers to review the original studies, including their study design, dose, population, and stated limitations, and to discuss any supplement decision with their own healthcare professional.

This article is provided for informational purposes only and does not constitute medical advice. It is not a claim about what any product does.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

References

  1. Aron, L., et al. (2025). Lithium deficiency and the onset of Alzheimer's disease. Nature. https://doi.org/10.1038/s41586-025-09335-x
  2. Vallée et al., 2021.
  3. Leeds, P. R. (2014). A new avenue for lithium: Intervention in traumatic brain injury. International Journal of Neuropsychopharmacology, 17(9), 1433–1440.
  4. Almeida, O. P., et al. (2022). Lithium and stroke recovery: A systematic review and meta-analysis of preclinical and clinical studies. Journal of Affective Disorders, 309, 182–194.
  5. DePaula, V. J. R. (2025). Lithium and neuroprotection: A review of molecular targets. Frontiers in Pharmacology.
  6. Kudrow, L. (1981). Lithium prophylaxis for chronic cluster headaches. Headache, 21(3), 132–135. https://doi.org/10.1111/j.1526-4610.1981.hed2103132.x
  7. Rybakowski, J. K. (2018). Neuroprotective effect of lithium: Implications for treatment of neurodegenerative disorders. Pharmacological Reports, 70(5), 936–942. https://doi.org/10.1016/j.pharep.2018.06.003
  8. Moore, G. J., et al. (2000). Lithium increases gray matter in human brain. Lancet, 356(9237), 1241–1242.
  9. Angelucci, F., et al. (2003). Chronic lithium treatment increases BDNF levels in the rat hippocampus. Neuropsychopharmacology, 28(2), 207–214. https://doi.org/10.1038/sj.npp.1300037
  10. Dwivedi, T., & Zhang, H. (2014). Lithium inhibits DNA methyltransferase 1 and increases BDNF expression in rat hippocampus. NeuroReport, 25(8), 495–499. https://doi.org/10.1097/WNR.0000000000000137
  11. [Citation pending verification — see note below]
  12. Sharma, R. P., Grayson, D. R., & Gavin, D. P. (2008). Histone deacetylase inhibitors and psychiatric disorders. American Journal of Psychiatry, 165(7), 830–843. https://doi.org/10.1176/appi.ajp.2008.07091479
  13. Hsu, L. K. G., et al. (1991). Lithium carbonate in the treatment of bulimia nervosa: A randomized, double-blind, placebo-controlled trial. International Journal of Eating Disorders, 10(3), 345–354.
  14. Sheard, M. H., & Wright, C. (1979). Lithium in the treatment of alcoholism and other drug abuse. Journal of Studies on Alcohol, 40(9), 795–802. https://doi.org/10.15288/jsa.1979.40.795
  15. Cipriani, A., et al. (2013). Lithium in the prevention of suicide in mood disorders: Updated systematic review and meta-analysis. BMJ, 346, f3646. https://doi.org/10.1136/bmj.f3646
  16. Blüml, V., et al. (2013). Lithium in the public water supply and suicide mortality and crime rates in Austria. The British Journal of Psychiatry, 203(5), 346–352. https://doi.org/10.1192/bjp.bp.112.113324
  17. Bowden, C. L., et al. (2010). A randomized, placebo-controlled, multicenter study of divalproex sodium and low-dose lithium for the treatment of bipolar II depression and hypomania. Journal of Affective Disorders, 127(1–3), 46–52. https://doi.org/10.1016/j.jad.2010.04.003
  18. Bowden, C. L., et al. (2005). Efficacy of low-dose lithium in the treatment of irritability and aggression in patients with mood disorders. Journal of Clinical Psychiatry, 66(3), 370–376. https://doi.org/10.4088/JCP.v66n0311
  19. Mintz, M., & Hollenberg, E. (2021). Lithium treatment of behavioral dysregulation in autism. Journal of Autism and Developmental Disorders, 51(9), 3396–3407. https://doi.org/10.1007/s10803-020-04808-2
  20. Nierenberg, A. A., et al. (2013). Lithium reduces anxiety in bipolar depression. Journal of Clinical Psychiatry, 74(3), 249–256. https://doi.org/10.4088/JCP.12m07719
  21. Kan, C., et al. (2013). Lithium treatment for post-traumatic stress disorder: A case series and literature review. International Clinical Psychopharmacology, 28(6), 336–340. https://doi.org/10.1097/YIC.0b013e3283642de6
  22. Young, A. H., et al. (2014). Low-dose lithium: A new approach to augment stress resilience? International Journal of Neuropsychopharmacology, 17(9), 1597–1603. https://doi.org/10.1017/S1461145714000431
  23. Schaffer, C. B., & Schaffer, L. C. (1999). Lithium augmentation for insomnia in mood disorder patients. Journal of Clinical Psychopharmacology, 19(5), 423–425. https://doi.org/10.1097/00004714-199910000-00015
  24. Donovan, S. J., et al. (2000). Adjunctive lithium carbonate in the treatment of children and adolescents with ADHD and severe mood dysregulation. Journal of the American Academy of Child & Adolescent Psychiatry, 39(5), 619–626. https://doi.org/10.1097/00004583-200005000-00012
  25. Premenstrual dysphoric disorder and lithium: https://pubmed.ncbi.nlm.nih.gov/39297265/
  26. Hamstra, S. I., et al. (2023). Beyond its psychiatric use: The benefits of low-dose lithium supplementation. Current Neuropharmacology, 21(4), 891–910. https://doi.org/10.2174/1570159X20666230419121400
  27. Matur, E., et al. (2025). Impact of lithium on the immune system: An investigation. Journal of Neuroimmunology.
  28. Toricelli, M., et al. (2020). Microdose lithium treatment reduced inflammatory factors in astrocytes. Journal of Neuroinflammation, 17, 125.
  29. Lundberg, M. (2020). Lithium and the interplay between telomeres, mitophagy, and aging mechanisms. Neuropsychopharmacology, 15, 100–110.
  30. Zarse, K., et al. (2011). Low-dose lithium uptake promotes longevity in humans and metazoans. European Journal of Nutrition, 50(5), 387–389. https://doi.org/10.1007/s00394-011-0171-x
  31. Iwata, N., et al. (2011). Low-dose lithium uptake promotes longevity in humans and metazoans. European Journal of Nutrition, 50(5), 387–389.
  32. Barjasteh-Askari, F., et al. (2020). Association of lithium in drinking water with the incidence of cardiovascular diseases: A nationwide ecological study in Japan. Environmental Research, 183, 109145. https://doi.org/10.1016/j.envres.2020.109145
  33. Hamstra, S. I., et al. (2023). Current Neuropharmacology, 21(4), 891–910.
  34. Hamstra, S. I., et al. (2023). Current Neuropharmacology, 21(4), 891–910.
  35. Liu, Y., et al. (2015). Low-dose lithium improves glucose homeostasis in diet-induced obese rats. Nutrients, 7(9), 8452–8469. https://doi.org/10.3390/nu7095384
  36. Davis, L. L., et al. (2005). Lithium augmentation in treatment-resistant depression: Effects on weight and appetite. Journal of Psychiatric Research, 39(4), 401–406. https://doi.org/10.1016/j.jpsychires.2004.10.001
  37. Vallée et al., 2020.
  38. Li, C., et al. (2011). Lithium chloride pretreatment attenuates acute liver injury in mice. International Immunopharmacology, 11(12), 2077–2083. https://doi.org/10.1016/j.intimp.2011.09.009
  39. Mongi, S., & Hadj-Tayeb, A. (2023). The role of lithium in gut microbiota modulation and neuroimmune regulation. Frontiers in Cellular Neuroscience, 17, 1180029. https://doi.org/10.3389/fncel.2023.1180029
  40. Sarkar, S., et al. (2005). Lithium induces autophagy to clear disease-associated proteins. Journal of Cell Biology, 170(7), 1101–1111.
  41. Clément-Lacroix, P., et al. (2005). Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. PNAS, 102(48), 17406–17411. https://doi.org/10.1073/pnas.0505259102
  42. Zhang, X., et al. (2014). Lithium prevents ovariectomy-induced osteoporosis in rats via Wnt signaling. Osteoporosis International, 25(12), 2943–2952. https://doi.org/10.1007/s00198-014-2826-0
  43. Martinsson, L., et al. (2016). Lithium treatment and risk of cancer in bipolar disorder: Population-based cohort study. BMJ Open, 6(1), e009043. https://doi.org/10.1136/bmjopen-2015-009043
  44. McAfee, J., et al. (2023). Lithium use and mortality in patients with cancer: A population-based cohort study. British Journal of Cancer, 128, 1224–1232. https://doi.org/10.1038/s41416-022-02105-2
  45. Lustgarten, J. S., et al. (1994). Lithium carbonate in the treatment of open-angle glaucoma: A pilot study. Journal of Glaucoma, 3(4), 276–280. https://doi.org/10.1097/00061198-199400340-00007
  46. Jiménez, F., et al. (1994). Lithium carbonate in the treatment of fibromyalgia: An open study. Revista de Investigación Clínica, 46(3), 201–206. PMID: 7992784
  47. Klein, P. S., & Melton, D. A. (1996). A molecular mechanism for the effect of lithium on development. PNAS, 93(16), 8455–8459. https://doi.org/10.1073/pnas.93.16.8455
  48. Albayrak, A., et al. (2013). Lithium prevents oxidative stress and cytokine imbalances in lung tissues in a sepsis model. Experimental and Therapeutic Medicine, 5(6), 1665–1670.